Daniel Mejia

Glucagon Like Peptide-1 (GLP-1) agonists exert their effect by inhibiting postprandial glucagon secretion, promoting glucose-dependent insulin secretion and mitigating food consumption by delaying gastric emptying…

Metabolic dysfunction-associated fatty liver disease (MAFLD) affects one in four people globally and is the primary cause of chronic liver disease. The cornerstone of treatment focuses on lifestyle modifications, including weight loss, diet, and exercise…